NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT04762979 2026-01-02
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Active not recruiting
NCT06083038 2025-12-31
Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib
HealthPartners Institute
Active not recruiting
NCT05090358 2025-10-27
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05143229 2025-10-06
ASSET
University of Kansas Medical Center
Phase 1 Active not recruiting
NCT05063786 2025-09-08
ALPHABET
Spanish Breast Cancer Research Group
Phase 3 Active not recruiting
NCT05625087 2025-08-20
SAFIR 03
UNICANCER
Phase 2 Active not recruiting
NCT01791478 2024-07-23
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Active not recruiting